13th Sep 2010 07:00
SPH.L Atopiclair® Cream receives reimbursement status in France. Product to be launched Sept 23rd
13th September 2010, Godalming, UK: Sinclair Pharma plc (the "Company" or "Sinclair": SPH:L), is pleased to announce that Atopiclair® Cream has been granted reimbursement status in France for the treatment of atopic dermatitis, a significant medical condition in young children (5% pediatric, 1% adult incidence in France). The company intends to launch the product in France on September 23rd, backed up by a strong promotional campaign.
French Health authorities have just included Atopiclair® Cream in the list of medical devices reimbursable by the French National Health System. This decision provides clinicians with an efficacious and safe solution in the management of mild to moderate atopic dermatitis symptoms for adults and infants above 6 months old. Atopiclair® will occupy a well-defined position in the market, as a novel and reimbursed complement to the usual symptomatic treatments for atopic dermatitis such as corticosteroids (c20m unit market) or emollients (c8m unit reimbursed market).
After a pre-marketing campaign to dermatologists last year, an extensive and IT intensive marketing plan has been developed by Sinclair's French team to ensure healthcare providers integrate Atopiclair® in their atopic dermatitis therapeutic schemes. For the first time, Sinclair medical representatives will promote Atopiclair®, its mode of action and clinical efficacy to hospitals, dermatologists, pediatricians and pharmacists using iPads, and via the Atopiclair website www.atopiclair.fr. An iPhone/iPad app will also be made available to support healthcare providers and facilitate patients' compliance.
Chris Spooner, Sinclair's CEO commented:
"Atopiclair® Cream's listing and reimbursement status is a direct result of the Company's significant investment in a comprehensive clinical development programme which demonstrated the product's safety and efficacy profiles.
Atopiclair® is a leading Sinclair brand, and from a commercial perspective the impending launch with reimbursement status in our primary market is very important. Earlier this year, I announced our intention to drive Sinclair's French business back into sustainable growth before calendar year end. In fact, as announced at last week's FY10 Prelim results, Sinclair's sales growth in France and elsewhere is already much improved following a strong start to FY11. The French launch of Atopiclair® will be the biggest event for the company this year and is a strong positive".
Ends
For further information please contact:
Sinclair Pharma plc Tel: +44 (0) 1483 410 600
Chris Spooner, CEO
Alan Olby, CFO
Singer Capital Markets Ltd Tel: +44 (0)20 3205 7500
Shaun Dobson
Claes Sp¥ng
Biddicks, Financial Public Relations Tel: +44 (0)20 7448 1000
Shane Dolan
Notes to Editors:
About Sinclair Pharma Plc www.sinclairpharma.com
Sinclair Pharma plc is an international, highly commercial, rapid-growth dermatology and oral care company providing and promoting high quality and differentiated products through growing sales and marketing operation that is present in France, Italy, Germany and Spain, and through an extensive marketing partner network across selected developed & emerging markets.
About Atopiclair®
Atopiclair® is a non-steroidal topical treatment indicated for the symptomatic relief of atopic, contact allergic and irritant dermatitis. Atopiclair® is part of Sinclair Pharma atopic dermatitis portfolio, along with Trid©sonit, its cortico-steroid (class II in France), and Dermachronic dermo-cosmetic range.
Atopiclair® provides relief and long term management of the most common signs and symptoms such as itching, redness, burning and pain in adults and children. It can be used alone or in combination with conventional therapy. The product has been formulated to replace key skin lipids and hydrate the skin, to support the normal skin barrier function which helps prevent recurrence and to calm itching and burning during flares
The Atopiclair® line is available as a cream & a lotion and is sold in more than 10 countries.
"Safe Harbor" Statement under the US Private Securities Litigation Reform Act of 1995: Some or all of the statements in this document that relate to future plans, expectations, events, performances and the like are forward-looking statements, as defined in the US Private Securities Litigation Reform Act of 1995. Actual results of events could differ materially from those described in the forward-looking statements due to a variety of factors.
vendorRelated Shares:
Sinclair Pharma